Eltoukhy Helmy, co-CEO of Guardant Health (GH), has filed 40 Form 4 transactions over the past year, all in a single company, with a pronounced sell-side bias. His total disclosed sales reached approximately $39.9 million, while he recorded zero open-market purchases and zero acquisitions during the period. The most concentrated selling occurred on June 5, 2026, when Helmy executed seven open-market sales (code S) totaling roughly $12.4 million, with individual transactions ranging from about $13,000 to $6.2 million. That cluster of sales represents the clearest signal of disposition, though it is part of a broader pattern of regular equity monetization.
The remaining recent activity is dominated by non-discretionary or mechanical transactions. On July 1, 2026, Helmy had shares withheld to cover tax obligations (code F) valued at $2.9 million, following option exercises (code M) with no cash value. Similar tax-withholding events occurred on June 30 ($214,000), April 1 ($1.6 million), March 31 ($132,000), March 13 ($1.2 million), and January 1 ($3.1 million across two filings). These F-code transactions are automatic and tied to vesting or exercise, not independent trading decisions. Helmy also received compensation grants (code A) on March 17, 2026, with no reported value.
The data shows no buying conviction whatsoever—zero P-code purchases—and a steady stream of sales, both open-market and tax-driven. The June 5 cluster stands out as the only concentrated discretionary selling, while the recurring F-code withholdings reflect routine equity compensation mechanics. Overall, Helmy’s Form 4 history at GH reveals a consistent pattern of reducing exposure through sales and tax withholdings, with no corresponding accumulation.
AI-assisted summary